Consort Medical PLC

Consort Medical PLC

Consort Medical PLC, led by CEO Jonathan Glenn and CFO Richard Cotton, operates as a contract development and manufacturing organization (CDMO) in the pharmaceutical sector. The company's history traces back to the 1970s, though its current corporate structure was established through a series of acquisitions that built its drug delivery device and respiratory product portfolio (per regulatory filings). Consort Medical focuses on two core business segments: Bespak, which designs and manufactures drug delivery devices such as inhalers, auto-injectors, and nasal spray pumps for pharmaceutical partners, and Aesica, a CDMO providing formulation development and manufacturing services for active pharmaceutical ingredients and finished dosage forms. The company serves clients across multiple therapeutic areas, including respiratory, central nervous system, and cardiovascular, with production sites in the UK, Germany, Italy, and the US (per public company documentation). Geographically, Consort Medical operates through its headquarters in Hemel Hempstead, UK, with additional offices in Schaffhausen, Switzerland; New Brunswick and Minneapolis, US; Guangzhou, China; Basel, Switzerland; Amsterdam, Netherlands; and Wien, Austria. The company employs thousands globally, though exact team size is not publicly specified. In recent years, Consort Medical has focused on expanding its capacity for high-value drug-device combination products (per industry reports). Structurally, Consort Medical differs from typical asset managers by operating as a public limited company (PLC) that generates revenue through manufacturing and service contracts rather than deployed capital. Its model is vertically integrated, combining R&D, regulatory expertise, and large-scale production, which provides pharmaceutical clients a single-source solution for complex drug delivery systems. This structural niche positions it as a specialized CDMO within the healthcare value chain.